Search

Your search keyword '"DiGiammarino, Enrico"' showing total 3 results
Start Over Author "DiGiammarino, Enrico" Publisher nature publishing group
3 results on '"DiGiammarino, Enrico"'

1. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Author

Lasko, Loren M., Jakob, Clarissa G., Edalji, Rohinton P., Qiu, Wei, Montgomery, Debra, Digiammarino, Enrico L., Hansen, T. Matt, Risi, Roberto M., Frey, Robin, Manaves, Vlasios, Shaw, Bailin, Algire, Mikkel, Hessler, Paul, Lam, Lloyd T., Uziel, Tamar, Faivre, Emily, Ferguson, Debra, Buchanan, Fritz G., Martin, Ruth L., Torrent, Maricel, Chiang, Gary G., Karukurichi, Kannan, Langston, J. William, Weinert, Brian T., Choudhary, Chunaram, de Vries, Peter, Van Drie, John H., McElligott, David, Kesicki, Ed, Marmorstein, Ronen, Sun, Chaohong, Cole, Philip A., Rosenberg, Saul H., Michaelides, Michael R., Lai, Albert, and Bromberg, Kenneth D.

Subjects
Transferases -- Health aspects, Tumors -- Care and treatment, Chemical inhibitors -- Usage -- Health aspects, Binding proteins -- Health aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Author(s): Loren M. Lasko [1]; Clarissa G. Jakob [1]; Rohinton P. Edalji [1]; Wei Qiu [1]; Debra Montgomery [1]; Enrico L. Digiammarino [1]; T. Matt Hansen [1]; Roberto M. Risi [...]

Published
2017
Full Text
View/download PDF

2. Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Author

Lasko, Loren M., Jakob, Clarissa G., Edalji, Rohinton P., Qiu, Wei, Montgomery, Debra, Digiammarino, Enrico L., and Hansen, T. Matt

Subjects
Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

In the originally published version of this Letter, the authors Arthur F. Kluge, Michael A. Patane and Ce Wang were inadvertently omitted from the author list. Their affiliations are: I-to-D, Inc., PO Box 6177, Lincoln, Massachusetts 01773, USA (A.F.K.); Mitobridge, Inc. 1030 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA (M.A.P.); and China Novartis Institutes for BioMedical Research, No. 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong District, Shanghai 201203, China (C.W.). These authors contributed to the interpretation of results and design of compounds. In addition, author 'Edward A. Kesicki' was misspelled as 'Ed Kesicki'. These errors have been corrected online., Author(s): Loren M. Lasko [sup.1] , Clarissa G. Jakob [sup.1] , Rohinton P. Edalji [sup.1] , Wei Qiu [sup.1] , Debra Montgomery [sup.1] , Enrico L. Digiammarino [sup.1] , T. [...]

Published
2018
Full Text
View/download PDF

3. An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.

Author

Chan S, Belmar N, Ho S, Rogers B, Stickler M, Graham M, Lee E, Tran N, Zhang D, Gupta P, Sho M, MacDonough T, Woolley A, Kim H, Zhang H, Liu W, Zheng P, Dezso Z, Halliwill K, Ceccarelli M, Rhodes S, Thakur A, Forsyth CM, Xiong M, Tan SS, Iyer R, Lake M, Digiammarino E, Zhou L, Bigelow L, Longenecker K, Judge RA, Liu C, Trumble M, Remis JP, Fox M, Cairns B, Akamatsu Y, Hollenbaugh D, Harding F, and Alvarez HM

Subjects
Animals, Cluster Analysis, Disease Models, Animal, Glucocorticoid-Induced TNFR-Related Protein agonists, Humans, Immunotherapy methods, Mice, Receptors, Tumor Necrosis Factor agonists, T-Lymphocytes, Neoplasms drug therapy, Programmed Cell Death 1 Receptor
Abstract

Costimulatory receptors such as glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) play key roles in regulating the effector functions of T cells. In human clinical trials, however, GITR agonist antibodies have shown limited therapeutic effect, which may be due to suboptimal receptor clustering-mediated signaling. To overcome this potential limitation, a rational protein engineering approach is needed to optimize GITR agonist-based immunotherapies. Here we show a bispecific molecule consisting of an anti-PD-1 antibody fused with a multimeric GITR ligand (GITR-L) that induces PD-1-dependent and FcγR-independent GITR clustering, resulting in enhanced activation, proliferation and memory differentiation of primed antigen-specific GITR + PD-1 + T cells. The anti-PD-1-GITR-L bispecific is a PD-1-directed GITR-L construct that demonstrated dose-dependent, immunologically driven tumor growth inhibition in syngeneic, genetically engineered and xenograft humanized mouse tumor models, with a dose-dependent correlation between target saturation and Ki67 and TIGIT upregulation on memory T cells. Anti-PD-1-GITR-L thus represents a bispecific approach to directing GITR agonism for cancer immunotherapy., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results